Mesoblast Ltd ASX:MSB:
REQUESTS MODULAR REVIEW OF BLA FOR REXLEMESTROCEL-L IN END-STAGE HEART FAILURE WITH LVAD
REXLEMESTROCEL-L RECEIVES ORPHAN DRUG AND RMAT DESIGNATIONS
Reuters
Mesoblast Requests Modular Review Of BLA For Rexlemestrocel-L In End-Stage Heart Failure With LVAD
- Sources
- Reuters
- Markets
- Stocks
- Active symbols
- ASX:MSB
- Language
- English
Mesoblast Ltd ASX:MSB: